- Home
- RIGL vs DGICB Comparison
RIGL vs DGICB Comparison
Compare RIGL & DGICB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- DGICB
- Stock Information
- Founded
- RIGL 1996
- DGICB 1986
- Country
- RIGL United States
- DGICB United States
- Employees
- RIGL N/A
- DGICB N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- DGICB Property-Casualty Insurers
- Sector
- RIGL Health Care
- DGICB Finance
- Exchange
- RIGL Nasdaq
- DGICB Nasdaq
- Market Cap
- RIGL 486.4M
- DGICB 491.5M
- IPO Year
- RIGL 2000
- DGICB N/A
- Fundamental
- Price
- RIGL $20.99
- DGICB $13.40
- Analyst Decision
- RIGL Buy
- DGICB
- Analyst Count
- RIGL 5
- DGICB 0
- Target Price
- RIGL $34.80
- DGICB N/A
- AVG Volume (30 Days)
- RIGL 216.6K
- DGICB 1.2K
- Earning Date
- RIGL 03-04-2025
- DGICB 02-20-2025
- Dividend Yield
- RIGL N/A
- DGICB 4.65%
- EPS Growth
- RIGL N/A
- DGICB 148.60
- EPS
- RIGL 0.22
- DGICB 0.74
- Revenue
- RIGL $157,374,000.00
- DGICB $979,119,004.00
- Revenue This Year
- RIGL $51.34
- DGICB N/A
- Revenue Next Year
- RIGL $15.75
- DGICB $5.78
- P/E Ratio
- RIGL $94.25
- DGICB $19.88
- Revenue Growth
- RIGL 21.65
- DGICB 7.44
- 52 Week Low
- RIGL $7.48
- DGICB $10.75
- 52 Week High
- RIGL $29.82
- DGICB $16.81
- Technical
- Relative Strength Index (RSI)
- RIGL 55.77
- DGICB 37.35
- Support Level
- RIGL $20.98
- DGICB $13.65
- Resistance Level
- RIGL $23.01
- DGICB $14.96
- Average True Range (ATR)
- RIGL 1.40
- DGICB 0.33
- MACD
- RIGL 0.31
- DGICB -0.10
- Stochastic Oscillator
- RIGL 70.13
- DGICB 0.00
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.